NASDAQ · GYRE
Healthcare · Biotechnology
$6.68
Up+$0.14 (+2.14%)
Updated Aug 16, 2026, 7:01 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
GYRE closed at $6.68 after 20 trading sessions, up 13.61% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $6.55 | $6.73 | $6.47 | $6.68 | 52.74K |
| Aug 13, 2026 | $6.70 | $6.77 | $6.44 | $6.54 | 48.97K |
| Aug 12, 2026 | $6.68 | $6.99 | $6.62 | $6.66 | 94.55K |
| Aug 11, 2026 | $6.76 | $6.925 | $6.58 | $6.64 | 50.22K |
| Aug 10, 2026 | $6.67 | $6.80 | $6.31 | $6.72 | 53.25K |
| Aug 7, 2026 | $6.41 | $6.69 | $6.28 | $6.67 | 68.09K |
| Aug 6, 2026 | $6.28 | $6.51 | $6.21 | $6.40 | 49.09K |
| Aug 5, 2026 | $6.19 | $6.27 | $6.10 | $6.23 | 35.25K |
| Aug 4, 2026 | $6.11 | $6.4625 | $6.11 | $6.15 | 63.21K |
| Aug 3, 2026 | $5.80 | $6.125 | $5.80 | $6.11 | 53.66K |
| Jul 31, 2026 | $5.85 | $5.884 | $5.62 | $5.75 | 48.38K |
| Jul 30, 2026 | $5.72 | $5.9455 | $5.72 | $5.81 | 45.64K |
| Jul 29, 2026 | $5.91 | $6.02 | $5.62 | $5.64 | 66.08K |
| Jul 28, 2026 | $6.13 | $6.16 | $5.91 | $5.99 | 31.88K |
| Jul 27, 2026 | $6.01 | $6.27 | $6.01 | $6.13 | 43.08K |
| Jul 24, 2026 | $6.03 | $6.0677 | $5.90 | $5.94 | 33.77K |
| Jul 23, 2026 | $5.87 | $6.04 | $5.86 | $6.01 | 38.26K |
| Jul 22, 2026 | $6.03 | $6.1033 | $5.85 | $5.94 | 86.3K |
| Jul 21, 2026 | $5.89 | $6.1383 | $5.87 | $6.06 | 35.87K |
| Jul 20, 2026 | $6.08 | $6.2086 | $5.82 | $5.88 | 52.77K |
The latest Smart Investors Daily articles mentioning GYRE.
GYRE research
Company profile and research snapshot.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 10, 2025 | Jefferies | Buy | — |
| Aug 26, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 7, 2026
Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +10.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Aug 7, 2026
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China’s CDE in May 2026 SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced financial results for the secon
Benzinga · Aug 7, 2026
Gyre Therapeutics (NASDAQ:GYRE) affirms FY2026 sales outlook from $100.500 million-$111.000 million to $100.500 million-$111.000 million vs $102.300 million estimate.
Benzinga · Aug 7, 2026
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.04) by 200 percent. The company reported quarterly sales of $29.105 million which beat
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GYRE.
